Mesenchymal Stem Cell-Derived Exosomes as a Neuroprotective and Neurorestorative Treatment Strategy for Traumatic Brain Injury

**AWARD AMOUNT:** $110,570

**THE TEAM**

- **Ben Biesterveld,** MD
  - Co-Investigator

- **Benjamin Buller,** PhD
  - Co-Principal Investigator

- **Aaron Williams,** MD
  - Co-Principal Investigator

- **Hasan Alam,** MD
  - Co-Principal Investigator

- **Gerry Higgins,** MD, PhD
  - Co-Investigator

**NEUROLOGY**

**GENERAL SURGERY**

**COMPUTATIONAL MEDICINE AND BIOINFORMATICS**

**THE PROBLEM**

Despite recent improvements in supporting and rehabilitative care for TBI, no pharmacological agents exist that are able to:

- Reduce TBI-associated mortality
- Improve neurologic outcomes following injury

**THE SOLUTION**

**Successful transition of exosomes into clinical use as an early treatment for TBI**

- High efficacy
- Safe + easy to administer
- Use in military and austere settings
- Reduction in associated multi-organ injuries
- Low-cost
- Potential for large scale production

**THE TECHNOLOGY**

The data generated from large animal model studies will advance MSC-derived exosome development and testing as an early TBI treatment.

- Test earlier administration strategies
- Assess the therapeutic effects of early administration
- Identify exosomes’ protective mechanisms of action in the brain